Navigation Links
Tekturna Infographic Released by d’Oliveira & Associates Imparts Potential Side Effects of Blood Pressure Drug
Date:4/18/2013

(PRWEB) April 18, 2013

Tekturna (aliskiren), produced by Novartis, is a once-daily pill used to treat high blood pressure (hypertension) and is the first “Renin Inhibitor” drug that regulates the renin enzyme in the kidney. This process assists by narrowing the blood vessels and removes water from the bloodstream in order to improve overall circulation (i). In 2011, the FDA determined that aliskiren products had been prescribed over 2.4 million times to over 451,000 patients in the United States (ii). According to the National Institutes of Health, Novartis has marketed aliskiren under the following names: Amturnide, TekAmlo, Tekturna, TekturnaHCT, and Valturna (iii).

According to a press release from Novartis, the company stopped its ALTITUDE medical study in December of 2011 because Tekturna increased the risk of nonfatal stroke, kidney complications, hyperkalemia, and hypotension in patients with Type-2 diabetes. The study was conducted on the part of Novartis in an effort to expand the uses of Tekturna due to the “product profitability in 2011 was negative (iv).” Additional adverse events were recorded by The Institute for Safe Medication Practices in there October of 2012 issue of Quarter Watch which stated that 100 cases of angioedema (swelling) were reported by Tekturna patients in the first quarter of 2012 (v). The same publication also detailed other cases that included one report of death, two reports labeled life threatening, 15 reports of hospitalization, and a final total of 237 Tekturna adverse event reports, “more than any other blood pressure medication (v).”

The infographic issued by d’Oliveira & Associates provides general information on Tekturna as well as lists possible side effects. Side effects allegedly connected to the high blood pressure drug may include: kidney complications, hyperkalemia, angioedema, heart attack, stroke, and/or birth defects. Visit the Tekturna page and view the infographic here: Tekturna Infographic

If you or a loved one has suffered any injuries after taking Tekturna, you may want to file a claim. You should find the best Tekturna lawyer because you may only have one chance at justice. A personal injury lawyer familiar with this blood pressure drug may be able to provide you with important personal and legal advice. d’Oliveira & Associates, P.C., is working with some of the more experienced dangerous drug lawyers who are handling these cases. Please contact the law offices of d’Oliveira & Associates, P.C. at 1-800-992-6878 or fill out a contact form for a free legal consultation.

Sources:
(i) http://www.tekturna.com/info/treating-high-blood-pressure.jsp
(ii) http://www.fda.gov/Drugs/DrugSafety/ucm300889.htm
(iii) http://www.nlm.nih.gov/medlineplus/druginfo/meds/a607039.html
(iv) http://www.novartis.com/newsroom/media-releases/en/2011/1572562.shtml
(v) http://www.ismp.org/NEWSLETTERS/ACUTECARE/showarticle.asp?id=32

Read the full story at http://www.prweb.com/releases/2013/4/prweb10644073.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. St Jude Retreats Releases New Infographic Which Reports Consequences of Drunk Driving
2. d'Oliveira & Associates Issues New Infographic on Xarelto Providing Current FDA and Medical Study Information
3. d'Oliveira & Associates Releases New Byetta Infographic on Potential Kidney and Pancreas Health Risks Associated with the Drug
4. IHC Specialty Benefits Releases an Affordable Care Act Infographic to Help Customers Determine Health Insurance Rebates
5. d'Oliveira & Associates Releases Zimmer Knee Infographic Providing Important Safety Information on High-Flex Knees
6. Loyola University New Orleans Presents a History of Nursing in its New Infographic: Nursing Evolution
7. Law Firm Issues Biomet Hip Infographic Warning Consumers About the Dangers of Biomet Hip Implants
8. d'Oliveira & Associates Releases Fresenius Infographic about the FDA Recall of NaturaLyte and GranuFlo
9. d’Oliveira & Associates Releases Mirena IUD Infographic Describing Bayer’s Deceptive Mirena Simple Style Campaign
10. MacGregor & Collins, LLP Releases New California DUI Infographic
11. Get New Patients, INC Releases New Infographic titled 'Are Negative Reviews Killing Your Medical Practice?"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... bible in homes across the world. Yisrayl says this generation is a time like no ... to turn to the Bible. , Yisrayl says he does not want to sound like ...
(Date:1/20/2017)... ... January 20, 2017 , ... Doctor C LLC, a company ... January ECRM trade show to continue the marketing and distribution of its product, The ... for providing 400 percent better absorption than traditional vitamin C supplements. At the trade ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... Lice Troopers, ... lice cases in families with school-aged children since the holiday season. , “It ... holidays with their families, sharing hugs and taking photos, which is the head-to-head gateway ...
(Date:1/20/2017)... FL (PRWEB) , ... January 20, 2017 , ... International ... of nutritional and bodybuilding supplements, announced it attended the January ECRM trade show in ... bodybuilder and nutritional scientist who was determined to create a line of products that ...
(Date:1/20/2017)... California (PRWEB) , ... January 20, 2017 , ... "TransFlare ... to use inside of Final Cut Pro X," said Christina Austin - CEO of ... the RED Dragon. Utilizing the Dragon Sensor,TransFlare 4K Mystique lens flare and light leak ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... 19, 2017 Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase ... The global anti-obesity drugs market is expected to ... the forecast period and CAGR of 38.7% in the second half ... a CAGR of 32.8% from 2016 to 2027. The market is ... $24,063 million in 2027. ...
(Date:1/19/2017)... -- Accuray Incorporated (Nasdaq: ARAY ) announced ... set the bar for excellence in customer satisfaction. The ... rating among radiation treatment delivery systems in the U.S., ... Briefing™. The most recent ratings trend also shows Accuray ... for 11 of the past 12 quarters. ...
(Date:1/19/2017)... LONDON , January 19, 2017 ... Grothey ; European Oncology & Haematology, 2016;12(Suppl 2):3-8; ... ... http://photos.prnewswire.com/prnh/20151014/276718LOGO) Published recently in ... the peer-reviewed journal from touchONCOLOGY, an article by ...
Breaking Medicine Technology: